Thyroid cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BRAF 15
• RET 8
• PI3K 0
• TP53 0
• TERT 0
• MAPK 1
• GLP-1 1
• AKT 0
• PTEN 0
• STAT3 0
• mTOR 0
• PD-1 5
• NTRK 2
• ERK 0
• PSMA 1
• RAS 1
• ALK 1
• EGFR 3
• MEK 1
• VEGF 2
• PD-L1 0
• JAK 0
• CTNNB1 0
• KRAS 1
• NRAS 2
• NRF2 0
• PPAR 0
• TROP2 3
• AMPK 0
• DLL3 2
• HIF-1 0
• PIK3CA 0
• ABL1 0
• DPP-4 0
• IL-6 1
• METTL3 0
• TNF 0
• YAP 0
• AXL 1
• EZH2 0
• FGFR 0
• JNK 0
• MET 1
• MYC 0
• PKM2 0
• ROS1 1
• SGLT2 0
• STING 0
• ATM 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CGRP 0
• CTLA-4 0
• CXCR4 0
• FAK 0
• HMGB1 0
• IDH 0
• IDO1 0
• NLRP3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,051 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Suspended

  Personalized Treatment in Thyroid Disorders

  NCT03517579· Johns Hopkins University· Updated 22 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Suspended

  Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

  NCT03975231· City of Hope Medical Center· Updated 15 Oct 2026

  “Accrual goal met”Registry text, quoted unchanged. Source

• Terminated

  HEC169096 in Participants With Advanced Solid Tumors

  NCT05451602· Sunshine Lake Pharma Co., Ltd.· Updated 14 Oct 2026

  “Sponsor strategic decision; the study will not continue.”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

  NCT05575440· Mayo Clinic· Updated 24 Sept 2026

  “Slow accrual; lack of eligible study participants”Registry text, quoted unchanged. Source

• Withdrawn

  RAman For Thyroid cancER

  NCT04040673· Gloucestershire Hospitals NHS Foundation Trust· Updated 17 Sept 2026

  “Covid19 halted study”Registry text, quoted unchanged. Source

• Suspended

  CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

  NCT07181720· Chongqing Precision Biotech Co., Ltd· Updated 11 Sept 2026

  “Sponsor stopped the study.”Registry text, quoted unchanged. Source

• Suspended

  Methimazole in Patients With Progressive Glioblastoma

  NCT05607407· Case Comprehensive Cancer Center· Updated 17 Aug 2026

  “On hold per study team”Registry text, quoted unchanged. Source

• Suspended

  Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

  NCT05453799· Northwestern University· Updated 14 Aug 2026

  “Per sponsor letter, due to a business decision based on reprioritization of their internal XmAb20717 programs, Xencor has determined that ECR003 activities must halt and no additional subjects may be enrolled”Registry text, quoted unchanged. Source

• Terminated

  Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

  NCT05591092· Mayo Clinic· Updated 11 Aug 2026

  “Slow accrual”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma

  NCT07911761· Mansoura University· Source

• Natural History Study of Children and Adults With Medullary Thyroid Cancer

  NCT01660984· National Cancer Institute (NCI)· Source

• Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

  NCT01005654· National Cancer Institute (NCI)· Source

• Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

  NCT07886905· Washington University School of Medicine· Source

• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

  NCT01896479· Exelixis· Source

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Source

• A Study of Avutometinib and Defactinib in People With Thyroid Cancer

  NCT06007924· Memorial Sloan Kettering Cancer Center· Source

• Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

  NCT07529080· University of Michigan Rogel Cancer Center· Source

• A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

  NCT07822880· Eli Lilly and Company· Source

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

• Transcriptomics of thyroid cancer.

  Eur Thyroid J, Oct 2026

• Per- and Polyfluoroalkyl Substances and Papillary Thyroid Carcinoma: An Integrative Study of Bioinformatics, Epidemiological Associations, and In Vitro Responses.

  Int J Mol Sci, Sept 2026

• Network based approach identifies miR-145-3p as a central regulatory hub associated to the progression from localized to metastatic medullary thyroid carcinoma.

  J Pathol, Sept 2026

• TCGA-based identification of prognostic biomarkers and candidate traditional Chinese medicine compounds in papillary thyroid carcinoma: An observational study.

  Medicine (Baltimore), Sept 2026

• Unique Thyroid Carcinoma With Somatic Inactivating TSC2 Mutations, Follicular and Melanocytic Differentiation and Distinct Morphologic Features.

  Am J Surg Pathol, Sept 2026

• Neutrophil-related gene signature predicts prognosis and immune microenvironment patterns in thyroid cancer.

  Adv Clin Exp Med, Sept 2026

• ATF4 and FGFR4 cooperatively support thyroid cancer progression and CAF-associated tumor-promoting features.

  Endocrine, Aug 2026

• The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches.

  Expert Rev Anticancer Ther, Jul 2026

• Integrative profiling of diverse post-translational modifications for prognostic stratification and personalized therapy in papillary thyroid cancer.

  Front Endocrinol (Lausanne), Jul 2026

• Comprehensive evaluation of angiogenesis-associated genes in papillary thyroid cancer using bulk RNA and single-cell sequencing data.

  Eur Arch Otorhinolaryngol, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.